Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.33 |
| ▸ | CTSA | P10619 | 5/20 | 0.33 |
| ▸ | EIF4EBP1 | Q13541 | 4/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334200 | 0.86 | GPBAR1 (0.33) | GPBAR1EIF4EBP1 | |
| SCHEMBL16858696 | 0.86 | ALDH1A1 (0.35) | CTSAEIF4EBP1ALDH1A1 | |
| SCHEMBL3338449 | 0.80 | GPBAR1 (0.33) | GPBAR1EIF4EBP1 | |
| SCHEMBL23800948 | 0.74 | GPBAR1 (0.35) | GPBAR1HCRTR1HCRTR2 | |
| SCHEMBL31683715 | 0.74 | GPBAR1 (0.35) | GPBAR1HCRTR1HCRTR2 | |
| SCHEMBL3334198 | 0.74 | IGF1R (0.34) | EIF4EBP1ALDH1A1 | |
| SCHEMBL3338412 | 0.73 | GPBAR1 (0.36) | GPBAR1 | |
| SCHEMBL3337316 | 0.69 | GPBAR1 (0.34) | GPBAR1EIF4EBP1 | |
| SCHEMBL16390811 | 0.68 | GPBAR1 (0.40) | GPBAR1 | |
| SCHEMBL3340027 | 0.68 | GPBAR1 (0.35) | GPBAR1EIF4EBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422310-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150183800-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183800-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | GPBAR1 76/4885CTSA 900/4885EIF4EBP1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.